Inspire Investing LLC Raises Stock Position in IQVIA Holdings Inc. $IQV

Inspire Investing LLC raised its stake in IQVIA Holdings Inc. (NYSE:IQV) by 1.8% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 19,434 shares of the medical research company’s stock after purchasing an additional 347 shares during the quarter. Inspire Investing LLC’s holdings in IQVIA were worth $3,063,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in IQV. Clal Insurance Enterprises Holdings Ltd boosted its holdings in shares of IQVIA by 436.7% in the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 161 shares of the medical research company’s stock valued at $28,000 after purchasing an additional 131 shares during the last quarter. Golden State Wealth Management LLC boosted its holdings in shares of IQVIA by 295.5% in the 1st quarter. Golden State Wealth Management LLC now owns 174 shares of the medical research company’s stock valued at $31,000 after purchasing an additional 130 shares during the last quarter. AllSquare Wealth Management LLC acquired a new position in shares of IQVIA during the 1st quarter valued at $33,000. Larson Financial Group LLC lifted its holdings in shares of IQVIA by 109.9% during the 1st quarter. Larson Financial Group LLC now owns 275 shares of the medical research company’s stock valued at $48,000 after acquiring an additional 144 shares in the last quarter. Finally, Atticus Wealth Management LLC acquired a new position in shares of IQVIA during the 2nd quarter valued at $52,000. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Price Performance

IQV opened at $198.35 on Friday. The company has a 50-day moving average of $189.02 and a 200-day moving average of $168.27. The company has a market capitalization of $33.72 billion, a P/E ratio of 28.70, a PEG ratio of 2.23 and a beta of 1.32. IQVIA Holdings Inc. has a 1-year low of $134.65 and a 1-year high of $237.34. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.84 and a current ratio of 0.84.

IQVIA (NYSE:IQV) last released its earnings results on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share for the quarter, topping the consensus estimate of $2.77 by $0.04. The company had revenue of $4.02 billion during the quarter, compared to the consensus estimate of $3.96 billion. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The company’s revenue was up 5.3% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.64 EPS. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. Equities analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Insider Transactions at IQVIA

In related news, insider Eric Sherbet sold 5,800 shares of the business’s stock in a transaction dated Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total transaction of $1,102,290.00. Following the completion of the sale, the insider owned 27,178 shares of the company’s stock, valued at $5,165,178.90. This represents a 17.59% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Keriann Cherofsky sold 549 shares of the business’s stock in a transaction dated Wednesday, July 23rd. The shares were sold at an average price of $191.53, for a total transaction of $105,149.97. Following the sale, the insider directly owned 2,910 shares of the company’s stock, valued at approximately $557,352.30. This represents a 15.87% decrease in their position. The disclosure for this sale can be found here. 1.60% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

IQV has been the topic of several recent research reports. Hsbc Global Res upgraded shares of IQVIA from a “hold” rating to a “strong-buy” rating in a report on Thursday. Robert W. Baird lifted their target price on shares of IQVIA from $159.00 to $196.00 and gave the company a “neutral” rating in a report on Wednesday, July 23rd. Weiss Ratings restated a “hold (c)” rating on shares of IQVIA in a report on Wednesday. Truist Financial lifted their target price on shares of IQVIA from $209.00 to $235.00 and gave the company a “buy” rating in a report on Wednesday, July 23rd. Finally, Mizuho lifted their target price on shares of IQVIA from $190.00 to $225.00 and gave the company an “outperform” rating in a report on Friday, July 25th. One investment analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have issued a Hold rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $236.45.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.